Exploiting the tumor phenotype using biodegradable submicron carriers of chemotherapeutic drugs.
Exploiting the tumor phenotype using biodegradable submicron carriers of chemotherapeutic drugs.
复制标题
DOI：
10.1615/critrevoncog.2014011518
复制
发表时间：
2014
影响因子：
--
通讯作者：
Salem AK
中科院分区：
文献类型：
--
作者：
Geary SM;Salem AK
肿瘤组织具有将其与健康组织区分开的特征，并且使其成为化疗药物（CTX）的亚微米载体的有吸引力的靶标。CTX通常以游离形式全身性施用至癌症患者，导致不希望的细胞毒性作用并对可递送的CTX剂量施加限制。为了提高CTX的治疗指数，目前临床使用的基于脂质体的CTX制剂比游离形式的CTX更具肿瘤特异性。然而，在临床中基于脂质体的化疗进展缓慢，并且在过去十年中没有批准的制剂。替代载体系统，如由生物可降解聚合物聚（乳酸-共-乙醇酸）（PLGA）制成的那些，已在临床前环境中进行了研究，结果很有希望。在这里，我们回顾了可生物降解的亚微米载体作为实体瘤的CTX递送载体的原理，特别关注脂质体和基于PLGA的载体，突出了每个系统的优点和缺点。
Tumor tissues possess characteristics that distinguish them from healthy tissues and make them attractive targets for submicron carriers of chemotherapeutic drugs (CTX). CTX are generally administered systemically in free form to cancer patients resulting in unwanted cytotoxic effects and placing limitations on the deliverable CTX dose. In an effort to raise the therapeutic index of CTX there are now liposome-based CTX formulations in clinical use that are more tumor specific than the free form of CTX. However, progression to liposome-based chemotherapy in the clinic has been slow and there have been no approved formulations introduced in the last decade. Alternative carrier systems such as those made from the biodegradable polymer poly(lactic-co-glycolic) acid (PLGA) have been investigated in preclinical settings with promising outcomes. Here we review the principle behind biodegradable submicron carriers as CTX delivery vehicles for solid tumors with a specific focUS on liposomes and PLGA-based carriers, highlighting the strengths and weaknesses of each system.